vs
Side-by-side financial comparison of Terreno Realty Corp (TRNO) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Terreno Realty Corp is the larger business by last-quarter revenue ($137.5M vs $70.6M, roughly 1.9× Viridian Therapeutics, Inc.\DE). Terreno Realty Corp runs the higher net margin — 115.1% vs -49.0%, a 164.1% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 32.6%).
Terreno Realty Corp is a publicly traded real estate investment trust that specializes in owning, operating, and acquiring high-quality industrial real estate assets. Its portfolio mainly includes distribution warehouses and logistics facilities located in high-demand coastal U.S. metropolitan markets, serving tenants across e-commerce, last-mile delivery, retail supply chain, and light manufacturing segments.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
TRNO vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $137.5M | $70.6M |
| Net Profit | $158.2M | $-34.6M |
| Gross Margin | — | — |
| Operating Margin | — | -56.7% |
| Net Margin | 115.1% | -49.0% |
| Revenue YoY | 32.6% | 81958.1% |
| Net Profit YoY | 107.9% | 54.9% |
| EPS (diluted) | $1.54 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $137.5M | — | ||
| Q3 25 | $116.2M | $70.6M | ||
| Q2 25 | $112.2M | — | ||
| Q1 25 | $110.4M | — | ||
| Q4 24 | $103.7M | — | ||
| Q3 24 | $99.6M | — | ||
| Q2 24 | $94.2M | — | ||
| Q1 24 | $85.0M | — |
| Q4 25 | $158.2M | — | ||
| Q3 25 | $103.4M | $-34.6M | ||
| Q2 25 | $93.3M | — | ||
| Q1 25 | $48.1M | — | ||
| Q4 24 | $76.1M | — | ||
| Q3 24 | $36.6M | — | ||
| Q2 24 | $35.7M | — | ||
| Q1 24 | $36.1M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -56.7% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 115.1% | — | ||
| Q3 25 | 88.9% | -49.0% | ||
| Q2 25 | 83.1% | — | ||
| Q1 25 | 43.6% | — | ||
| Q4 24 | 73.4% | — | ||
| Q3 24 | 36.8% | — | ||
| Q2 24 | 37.9% | — | ||
| Q1 24 | 42.4% | — |
| Q4 25 | $1.54 | — | ||
| Q3 25 | $1.00 | — | ||
| Q2 25 | $0.90 | — | ||
| Q1 25 | $0.47 | — | ||
| Q4 24 | $0.78 | — | ||
| Q3 24 | $0.37 | — | ||
| Q2 24 | $0.37 | — | ||
| Q1 24 | $0.40 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $25.0M | $490.9M |
| Total DebtLower is stronger | $943.3M | — |
| Stockholders' EquityBook value | $4.1B | $503.0M |
| Total Assets | $5.4B | $577.1M |
| Debt / EquityLower = less leverage | 0.23× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $25.0M | — | ||
| Q3 25 | $26.2M | $490.9M | ||
| Q2 25 | $128.4M | — | ||
| Q1 25 | $156.5M | — | ||
| Q4 24 | $18.1M | — | ||
| Q3 24 | $243.7M | — | ||
| Q2 24 | $182.0M | — | ||
| Q1 24 | $649.6M | — |
| Q4 25 | $943.3M | — | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $742.4M | — | ||
| Q1 25 | $741.9M | — | ||
| Q4 24 | $823.4M | — | ||
| Q3 24 | $672.2M | — | ||
| Q2 24 | $772.0M | — | ||
| Q1 24 | $771.8M | — |
| Q4 25 | $4.1B | — | ||
| Q3 25 | $4.0B | $503.0M | ||
| Q2 25 | $3.9B | — | ||
| Q1 25 | $3.9B | — | ||
| Q4 24 | $3.7B | — | ||
| Q3 24 | $3.6B | — | ||
| Q2 24 | $3.4B | — | ||
| Q1 24 | $3.4B | — |
| Q4 25 | $5.4B | — | ||
| Q3 25 | $5.3B | $577.1M | ||
| Q2 25 | $5.0B | — | ||
| Q1 25 | $4.9B | — | ||
| Q4 24 | $4.8B | — | ||
| Q3 24 | $4.6B | — | ||
| Q2 24 | $4.5B | — | ||
| Q1 24 | $4.4B | — |
| Q4 25 | 0.23× | — | ||
| Q3 25 | 0.26× | — | ||
| Q2 25 | 0.19× | — | ||
| Q1 25 | 0.19× | — | ||
| Q4 24 | 0.22× | — | ||
| Q3 24 | 0.19× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.22× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $271.9M | $-84.6M |
| Free Cash FlowOCF − Capex | — | $-84.7M |
| FCF MarginFCF / Revenue | — | -120.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | 1.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $271.9M | — | ||
| Q3 25 | $79.5M | $-84.6M | ||
| Q2 25 | $60.6M | — | ||
| Q1 25 | $61.4M | — | ||
| Q4 24 | $232.7M | — | ||
| Q3 24 | $70.0M | — | ||
| Q2 24 | $64.3M | — | ||
| Q1 24 | $47.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $-84.7M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -120.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 1.72× | — | ||
| Q3 25 | 0.77× | — | ||
| Q2 25 | 0.65× | — | ||
| Q1 25 | 1.28× | — | ||
| Q4 24 | 3.06× | — | ||
| Q3 24 | 1.91× | — | ||
| Q2 24 | 1.80× | — | ||
| Q1 24 | 1.30× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TRNO
| Disposal Group Disposed Of By Sale Not Discontinued Operations | $109.5M | 80% |
| Other | $23.8M | 17% |
| At Market Equity Offering Program500Million | $4.1M | 3% |
VRDN
Segment breakdown not available.
